High-content micronucleus assay in genotoxicity profiling: Initial-stage development and some applications in the investigative/lead-finding studies in drug discovery

Toxicological Sciences

Volumn 118, Issue 1, 2010, Pages 71-85

  Mondal, Madhu S ^a   Gabriels, Joseph ^a   McGinnis, Claudia ^a,e   Magnifico, Maria ^a   Marsilje, Thomas H ^b   Urban, Laszlo ^a   Collis, Alan ^c   Bojanic, Dejan ^a   Biller, Scott A ^a   Frieauff, Wilfried ^d   Martus, Hans Joerg ^d   Suter, Willi ^d   Bentley, Philip ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c Novartis   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Early and Investigative Safety   (Switzerland)

Author keywords

Aneugens and clastogens; High content micronucleus; Investigative genotoxicity; Lead optimization; Marketed drugs; Structure genotoxicity

Indexed keywords

ACICLOVIR; ADRENALIN; AMITRIPTYLINE; AMOXAPINE; ASTEMIZOLE; CETIRIZINE; CIPROFLOXACIN; CODEINE; CYTOCHALASIN B; DESLORATADINE; DILTIAZEM; FENCLOFENAC; IDEBENONE; IMIPRAMINE; LAMIVUDINE; METOCLOPRAMIDE; MITOMYCIN C; ONDANSETRON; PROMETHAZINE; RANITIDINE; SERTRALINE; SILDENAFIL; SULFAMETHOXAZOLE; TEMOZOLOMIDE; THALIDOMIDE; TRIMETHOPRIM; UNINDEXED DRUG; VALACICLOVIR; WARFARIN; ZIDOVUDINE;

ALLERGY; ANAPHYLAXIS; ANIMAL CELL; ANIMAL TESTING REFINEMENT; ARTICLE; CELL ASSAY; CELL GROWTH; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DEPRESSION; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG SOLUBILITY; ERECTILE DYSFUNCTION; FEMALE; GENE EXPRESSION PROFILING; GENOTOXICITY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYPERTENSION; INFLAMMATION; LABORATORY AUTOMATION; LEPROSY; LYMPHOBLASTOID CELL; METABOLIC ACTIVATION; MICRONUCLEUS TEST; MOUSE; NEOPLASM; NONHUMAN; PEPTIC ULCER; PREDICTION; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RAT; REPRODUCIBILITY; TURNAROUND TIME; VALIDATION STUDY; VOMITING;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG TOXICITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; MICRONUCLEUS TESTS; PHARMACEUTICAL PREPARATIONS; REPRODUCIBILITY OF RESULTS;

CRICETULUS GRISEUS;

EID: 77958514290     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfq181     Document Type: Article

References (40)

1. Aardema, M. J. (1993). Updated worldwide regulatory guidelines for genotoxicity testing-workshop proceedings from the 1992 Environmental Mutagen Society Meeting-introduction. Environ. Mol. Mutagen. 21, 1.
2. Blakey, D., Galloway, S. M., Kirkland, D. J., and MacGregord, J. T. (2008). Regulatory aspects of genotoxicity testing: from hazard identification to risk assessment. Mutat. Res. 657, 84-90.
3. Bonassi, S., Fenech, M., Lando, C., Lin, Y. P., Ceppi, M., Chang, W. P., Holland, N., Kirsch-Volders, M., Zeiger, E., Ban, S. Y., et al. (2001). HUman MicroNucleus Project: international database comparison for results with the cytokinesis-block micronucleus assay in human lymphocytes: I. Effect of laboratory protocol, scoring criteria, and host factors on the frequency of micronuclei. Environ. Mol. Mutagen. 37, 31-45.
4. Brambilla, G., and Martelli, A. (2009). Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals [Review]. Mutat. Res. 681, 209-229.
5. Bryce, S., Phonethepswath, S., Avlasevich, S., Bemis, J., and Dertinger, S. (2008). Miniaturization and further automation of the in vitro micronucleus assay. Environ. Mol. Mutagen. 49, 567.
6. Burke, D. A., Wedd, D. J., and Burlinson, B. (1996). Use of the Miniscreen assay to screen novel compounds for bacterial mutagenicity in the pharmaceutical industry. Mutagenesis 11, 201-205.
7. Cao, F., Zhou, T., Simpson, D., Zhou, Y. C., Boyer, J., Chen, B., Jin, T. Y., Cordeiro-Stone, M., and Kaufmann, W. (2007). p53-dependent but ATMindependent inhibition of DNA synthesis and G2 arrest in cadmium-treated human fibroblasts. Toxicol. Appl. Pharmacol. 218, 174-185.
8. Cariello, N. F., and Piegorsch, W. W. (1996). The Ames test: the two-fold rule revisited. Mutat. Res. 369, 23-31.
9. Chao, J. I., and Yang, J. L. (2001). Opposite roles of ERK and p38 mitogenactivated protein kinases in cadmium-induced genotoxicity and mitotic arrest. Chem. Res. Toxicol. 14, 1193-1202.
10. Combes, R. D. (1995). Regulatory genotoxicity testing-a critical appraisal. Altern. Lab. Anim. 23, 352-379.
11. Custer, L. L., and Sweder, K. S. (2008). The role of genetic toxicology in drug discovery and optimization. Curr. Drug Metab. 9, 978-985.
12. Dertinger, S., Bryce, S., Avlasevich, S., Bemis, J., De Boeck, M., Van Goethem, F., Beerens, D., Aerts, H., Collins, J., Ellis, P., et al. (2007). Multilaboratory evaluation of an automated, high content in vitro micronucleus assay. Environ. Mol. Mutagen. 48, 616.
13. Diaz, D., Scott, A., Carmichael, P., Shi, W., and Costales, C. (2007). Evaluation of an automated in vitro micronucleus assay in CHO-K1 cells. Mutat. Res. 630, 1-13.
14. Fenech, M. (1993). The cytokinesis-block micronucleus technique-a detailed description of the method and its application to genotoxicity studies in human-populations. Mutat. Res. 285, 35-44.
15. Fenech, M., Chang, W. P., Kirsch-Volders, M., Holland, N., Bonassi, S., and Zeiger, E. (2003). HUMN project: detailed description of the scoring criteria for the cytokinesis-block micronucleus assay using isolated human lymphocyte cultures. Mutat. Res. 534, 65-75.
16. Fenech, M., and Morley, A. A. (1986). Cytokinesis-block micronucleus method in human lymphocytes: effect of in vivo aging and low-dose X-irradiation. Mutat. Res. 161, 193-198.
17. Frieauff, W., Potter-Locher, F., Cordier, A., and Suter, W. (1998). Automatic analysis of the in vitro micronucleus test on V79 cells. Mutat. Res. 413, 57-68.
18. Frieauff, W., and Romagna, F. (1994). Technical aspects of automatic micronucleus analysis in rodent bone-marrow assays. Cell Biol. Toxicol. 10, 283-289.
19. Giannotti, E., Vandin, L., Repeto, P., and Comelli, R. (2002). A comparison of the in vitro Comet assay with the in vitro chromosome aberration assay using whole human blood or Chinese hamster lung cells: validation study using a range of novel pharmaceuticals. Mutagenesis 17, 163-170.
20. ICH Guideline. (1997). Genotoxicity: a standard battery for genotoxicity testing of pharmaceuticals. ICH2B. ICH.
21. ICH Guideline. (2008). Guidance on genotoxicity testing and data interpretation for pharmaceuticals intended for human use. ICHS2(R1). ICH.
22. Kirkland, D., Aardema, M., Henderson, L., and Muller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens-I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584, 1-256.
23. Kirkland, D., Aardema, M., Muller, L., and Hayashi, M. (2006). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat. Res. 608, 29-42.
24. Kirsch-Volders, M., Sofuni, T., Aardema, C., Albertini, S., Eastmond, D., Fenech, M., Ishidate, M., Kirchner, S., Lorge, E., Morita, T., et al. (2003). Report from the in vitro micronucleus assay working group. Mutat. Res. 540, 153-163.
25. Liu, Y., and Huang, H. (1997). Involvement of calcium-dependent protein kinase C in arsenite-induced genotoxicity in Chinese hamster ovary cells. J. Cell. Biochem. 64, 423-433.
26. Madle, S. (1994). Series-Current Issues in Mutagenesis and Carcinogenesis. 47. Strategies and philosophies of genotoxicity testing-highly sophisticated versus pragmatic regulatory approaches strategies and philosophies of genotoxicity testing-what is the question-reply. Mutat. Res. 308, 111-112.
27. Muller, L., and Kasper, P. (2000). Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat. Res. 464, 19-34.
28. Muller, L., Kikuchi, Y., Probst, G., Schechtman, L., Shimada, H., Sofuni, T., and Tweats, D. (1999). ICH-harmonised guidances on genotoxicity testing of pharmaceuticals: evolution, reasoning and impact. Mutat. Res. 436, 195-225.
29. Nesslany, F., and Marzin, D. (1999). A micromethod for the in vitro micronucleus assay. Mutagenesis 14, 403-410.
30. Olaharski, A. J., Gonzaludo, N., Bitter, H., Goldstein, D., Kirchner, S., Uppal, H., and Kolaja, K. (2009). Identification of kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors. PLoS Comput. Biol.5(7), e1000446.
31. Organization for Economic Cooperation and Development Guideline. (2004). Draft Proposal for a New Guideline 487, In Vitro Micronucleus Test. In OECD Guideline for the Testing of Chemicals. Paris, Organization for Economic Cooperation and Development.
32. Phelps, J. B., Garriott, M. L., and Hoffman, W. P. (2002). A protocol for the in vitro micronucleus test-II. Contributions to the validation of a protocol suitable for regulatory submissions from an examination of 10 chemicals with different mechanisms of action and different levels of activity. Mutat. Res. 521, 103-112.
33. Scott, A., Malcomber, S., Maskell, S., Moore, C., Windebank, S., Diaz, D., and Carmichael, P. (2007). An assessment of the performance of an automated scoring system (Cellomics) for the in vitro micronucleus assay in CHO-K1 cells. Toxicology 231, 111-112.
34. Snyder, R. D., and Green, J. W. (2001). A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488, 151-169.
35. Surralles, J., Xamena, N., Creus, A., Catalan, J., Norppa, H., and Marcos, R. (1995). Induction of micronuclei by 5 pyrethroid insecticides in whole-blood and isolated human lymphocyte cultures. Mutat. Res. 341, 169-184.
36. Suter, W. (2006). Predictive value of in vitro safety studies. Curr. Opin. Chem. Biol. 10, 362-366.
37. Thybaud, V., Aardema, M., Clements, J., Dearfield, K., Galloway, S., Hayashi, M., Jacobson-Kram, D., Kirkland, D., MacGregor, J. T., Marzin, D., et al. (2007). Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing. Mutat. Res. 627, 41-58.
38. Tice, R. R., Agurell, E., Anderson, D., Burlinson, B., Hartmann, A., Kobayashi, H., Miyamae, Y., Rojas, E., Ryu, J. C., and Sasaki, Y. F. (2000). Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35, 206-221.
39. Tweats, D. J. (1998). Impact of ICH guidelines on genotoxicity testing. Pharm. Sci. Technol. Today 1, 181-183.
40. Walmsley, R. M. (2008). GADD45a-GFP GreenScreen HC genotoxicity screening assay. Expert Opin. Drug Metab. Toxicol. 4, 827-835.